Ipilimumab for the treatment of metastatic prostate cancer.

about

Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses.Recent Advances in Prostate Cancer Treatment and Drug Discovery.

P2860

Q52599425-3893E60D-DEE5-424A-A4E7-98CFCBAD2A7F Q54111821-E59D0F4D-6D80-433F-ACB6-76743201F6B7

P2860

Ipilimumab for the treatment of metastatic prostate cancer.

Item

http://www.wikidata.org/entity/Q47225399

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ipilimumab for the treatment of metastatic prostate cancer.

@en

Ipilimumab for the treatment of metastatic prostate cancer.

@nl

type

Item

label

Ipilimumab for the treatment of metastatic prostate cancer.

@en

Ipilimumab for the treatment of metastatic prostate cancer.

@nl

prefLabel

Ipilimumab for the treatment of metastatic prostate cancer.

@en

Ipilimumab for the treatment of metastatic prostate cancer.

@nl

P1476

Ipilimumab for the treatment of metastatic prostate cancer.

@en

P2093

Concetta Alaia

http://www.w3.org/2001/XMLSchema#string

Evzen Amler

http://www.w3.org/2001/XMLSchema#string

Lucio Quagliuolo

http://www.w3.org/2001/XMLSchema#string

Silvia Zappavigna

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

A Perspective of Immunotherapy for Prostate Cancer

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14712598.2018.1420777

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Michele Caraglia

Sabrina Rossetti

Gaetano Facchini

Mariarosaria Boccellino

P577

2017-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29271259

http://www.w3.org/2001/XMLSchema#string

P921

Ipilimumaab

Ipilimumab for the treatment of metastatic prostate cancer.

about

P2860

P2860

Ipilimumab for the treatment of metastatic prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698

P921